IDNNA

IDNNA
Names
Preferred IUPAC name
1-(4-Iodo-2,5-dimethoxyphenyl)-N,N-dimethylpropan-2-amine
Other names
2,5-Dimethoxy-4-iodo-N,N-dimethylamphetamine
2,5-Dimethoxy-4-iodo-1-ethyl-(α-methyl)amine; N,N-Dimethyl-DOI
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C13H20INO2/c1-9(15(2)3)6-10-7-13(17-5)11(14)8-12(10)16-4/h7-9H,6H2,1-5H3 checkY
    Key: XBCUSBRGRALQID-UHFFFAOYSA-N checkY
  • InChI=1/C13H20INO2/c1-9(15(2)3)6-10-7-13(17-5)11(14)8-12(10)16-4/h7-9H,6H2,1-5H3
    Key: XBCUSBRGRALQID-UHFFFAOYAY
  • Ic1cc(OC)c(cc1OC)CC(N(C)C)C
Properties
C13H20NO2I
Molar mass 349.211 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)
Infobox references

IDNNA, also known as 2,5-dimethoxy-4-iodo-N,N-dimethylamphetamine or as N,N-dimethyl-DOI, is a lesser-known psychedelic drug and a substituted amphetamine. It is also the N,N-dimethyl analog of DOI. IDNNA was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 2.6 mg, and the duration unknown.[1] IDNNA produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of IDNNA.

Society and culture

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

References

  1. ^ IDNNA Entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.